![Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets](https://mma.prnewswire.com/media/1916090/Pierre_Fabre_Gennisium__Logo.jpg?p=twitter)
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
![Dexeryl Creme von PIERRE FABRE DERMO KOSMETIK GmbH GB - DUCRAY A-DERMA PFD Spitzweg-Apotheke Herzogenrath Dexeryl Creme von PIERRE FABRE DERMO KOSMETIK GmbH GB - DUCRAY A-DERMA PFD Spitzweg-Apotheke Herzogenrath](https://cdn1.apopixx.de/1000/web_schraeg/07379385.jpg)
Dexeryl Creme von PIERRE FABRE DERMO KOSMETIK GmbH GB - DUCRAY A-DERMA PFD Spitzweg-Apotheke Herzogenrath
![Pierre Fabre's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile Pierre Fabre's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile](https://image4.owler.com/logo/pierre-fabre_owler_20160408_092926_original.jpg)
Pierre Fabre's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
![Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire](https://mms.businesswire.com/media/20220705005255/en/1504255/23/Urovant_Pierre-Fabre_LogoLockup-01.jpg)
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire
![Bormioli Pharma and Pierre Fabre Develop a 100% Recycled PET packaging for ELUDRIL® Brand Mouthwashes - EU Business News Bormioli Pharma and Pierre Fabre Develop a 100% Recycled PET packaging for ELUDRIL® Brand Mouthwashes - EU Business News](https://www.eubusinessnews.com/wp-content/themes/wp-bootstrap-starter/aigm-image-handler/handler.gz?src=https%3A%2F%2Fwww.eubusinessnews.com%2Fwp-content%2Fuploads%2F2022%2F10%2FBormioli-Pharma.jpg&width=654&height=auto&format=webp)